fda semaglutide compounding says that the GLP-1 shortage is over Important Update: Changes to Compounded

Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure

Hims announced on February 5, 2026, that it would expand its weight-loss offering by enabling providers to prescribe a compounded semaglutide pill, with an introductory price of $49 for the first month, then $99 per month on a multi-month plan

Currently, there is no FDA-approved indication for GLP-1 receptor agonists or GIP/GLP-1 dual agonists specifically for lipedema treatment, and high-quality clinical trial evidence remains limited

Maintaining weight loss after discontinuation requires sustained lifestyle changes including dietary modifications and regular physical activity